Agomelatine in the Treatment of Major Depressive Disorder Potential for Clinical Effectiveness

被引:123
作者
Kennedy, Sidney H. [1 ,2 ]
Rizvi, Sakina J. [1 ,3 ,4 ]
机构
[1] Univ Hlth Network, Dept Psychiat, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada
[4] Univ Toronto, Dept Neurosci, Toronto, ON, Canada
关键词
SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED TRIAL; INDUCED SEXUAL DYSFUNCTION; STAR-ASTERISK-D; ANTIDEPRESSANT TREATMENT; PRIMARY-CARE; DOUBLE-BLIND; 2ND-GENERATION ANTIDEPRESSANTS; RELAPSE PREVENTION; RANDOMIZED TRIAL;
D O I
10.2165/11534420-000000000-00000
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To demonstrate the clinical effectiveness of an antidepressant drug requires evidence beyond short- and long-term efficacy, including a favourable adverse-effect profile and sustained treatment adherence. Under these conditions, patients should experience enhanced social and functional outcomes. The novel antidepressant agomelatine, a melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonist activity, displays antidepressant efficacy with a favourable adverse-effect profile that is associated with good patient adherence. Specifically, agomelatine has demonstrated significant short-term (6-8 weeks) and sustained (6 months) antidepressant efficacy relative to placebo, as well as evidence of relapse prevention (up to 10 months). In head-to-head comparative studies with venlafaxine and sertraline, there was evidence of early (at 1-2 weeks) and sustained (at 6 months) advantages for agomelatine. In addition to evidence of early efficacy, agomelatine also restored disturbed sleep-wake patterns early in treatment. There was no evidence of antidepressant-induced sexual dysfunction, weight gain or discontinuation-emergent symptoms. Agomelatine has demonstrated a range of properties that suggest it could offer advantages over current treatments for major depressive disorder, although further comparative trials are still required, as is evidence from real-world clinical practice.
引用
收藏
页码:479 / 499
页数:21
相关论文
共 85 条
[1]   Explaining patients' beliefs about the necessity and harmfulness of antidepressants [J].
Aikens, James E. ;
Nease, Donald E., Jr. ;
Klinkman, Micbael S. .
ANNALS OF FAMILY MEDICINE, 2008, 6 (01) :23-29
[2]   Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care [J].
Aikens, JE ;
Kroenke, K ;
Swindle, RW ;
Eckert, GJ .
GENERAL HOSPITAL PSYCHIATRY, 2005, 27 (04) :229-236
[3]   Adherence to antidepressant treatment among privately insured patients diagnosed with depression [J].
Akincigil, Ayse ;
Bowblis, John R. ;
Levin, Carrie ;
Walkup, James T. ;
Jan, Saira ;
Crystal, Stephen .
MEDICAL CARE, 2007, 45 (04) :363-369
[4]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[5]   Provider and patient characteristics associated with antidepressant nonadherence: The impact of provider specialty [J].
Bambauer, Kara Zivin ;
Soumerai, Stephen B. ;
Adams, Alyce S. ;
Zhang, Fang ;
Ross-Degnan, Dennis .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (06) :867-873
[6]   The ELIXIR study:: evaluation of sexual dysfunction in 4557 depressed patients in France [J].
Bonierbale, M ;
Lançon, C ;
Tignol, J .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (02) :114-124
[7]   Beliefs about antidepressant medications in primary care patients - Relationship to self-reported adherence [J].
Brown, C ;
Battista, DR ;
Bruehlman, R ;
Sereika, SS ;
Thase, ME ;
Dunbar-Jacob, J .
MEDICAL CARE, 2005, 43 (12) :1203-1207
[8]   Discontinuation of use and switching of antidepressants - Influence of patient-physician communication [J].
Bull, SA ;
Hu, XH ;
Hunkeler, EM ;
Lee, JY ;
Ming, EE ;
Markson, LE ;
Fireman, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (11) :1403-1409
[9]   Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis [J].
Cipriani, Andrea ;
Furukawa, Toshiaki A. ;
Salanti, Georgia ;
Geddes, John R. ;
Higgins, Julian P. T. ;
Churchill, Rachel ;
Watanabe, Norio ;
Nakagawa, Atsuo ;
Omori, Ichiro M. ;
McGuire, Hugh ;
Tansella, Michele ;
Barbui, Corrado .
LANCET, 2009, 373 (9665) :746-758
[10]   Prevalence of sexual dysfunction among newer antidepressants [J].
Clayton, AH ;
Pradko, JF ;
Croft, HA ;
Montano, CB ;
Leadbetter, RA ;
Bolden-Watson, C ;
Bass, KI ;
Donahue, RMJ ;
Jamerson, BD ;
Metz, A .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (04) :357-366